ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03771781
Recruitment Status : Completed
First Posted : December 11, 2018
Last Update Posted : December 11, 2018
Sponsor:
Information provided by (Responsible Party):
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary:
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Empagliflozin Tablets Drug: Empagliflozin Tab 25 MG Not Applicable

Detailed Description:
A Single-Center,Open-Label,Randomized,Single-Dose,Two-Period,Two-Sequence,Crossover Study to Assess the Bioequivalence of Test Formulation Empagliflozin Tablets with Reference Formulation Jardiance® in Chinese Healthy Adult Subjects under Fasting and Fed Conditions.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Test Formulation Empagliflozin Tablets 25 mg With Reference Formulation JARDIANCE® 25 mg in Healthy Adult Subjects.
Actual Study Start Date : April 16, 2018
Actual Primary Completion Date : May 25, 2018
Actual Study Completion Date : May 25, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Empagliflozin Tablets
The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
Drug: Empagliflozin Tablets
Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.

Empagliflozin Tab 25 MG
The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
Drug: Empagliflozin Tab 25 MG
Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®).




Primary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) [ Time Frame: 0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours ]
    Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data.


Secondary Outcome Measures :
  1. Area under the plasma concentration versus time curves (AUC) [ Time Frame: 0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours ]
    Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male or female, age 18 to 50 years, inclusive.
  2. The body weight of male is not less than 50kg, and female is not less than 45kg. All participants' body mass index (BMI) is between 19~26.
  3. Subjects are fully informed and voluntarily consent to participate in this study.
  4. Volunteers can communicate well with researchers and comply with the requirements of this study.

Exclusion Criteria:

  1. Any with chronic or active gastrointestinal diseases such as esophageal diseases, gastritis, gastric ulcers, enteritis, active gastrointestinal bleeding or got any digestive tract surgery within three years.
  2. Any disease previously or currently suffering from circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, and metabolic abnormalities, and which the researchers believe can interfere with the results of the test.
  3. Any history of allergy to drugs, food, or other substances.
  4. Dysphagia, difficulty in collecting blood or halo needle, history of dizziness.
  5. Those who have undergone surgery during the first four weeks of the trial or are scheduled to perform surgery during the study period.
  6. Those who has taken any drug (including vitamin products, Chinese herbs) within 14 days before the study.
  7. Those who use any inhibits or induces hepatic metabolism within 30 days before the study.
  8. Those who participated in any clinical drug trial within 3 months prior to the trial.
  9. Those who donated or lose massive blood within 3 months before the study (> 450 ml).
  10. Pregnant and lactating women.
  11. Male subjects (or their partners) or female subjects had unprotected sex or pregnancy plans within 2 weeks before screening and 6 months after the end of the trial, Those who are unwilling to use one or more non-drug contraceptive methods (e. G. Complete abstinence, contraceptive ring, partner ligation, etc.) during the study.
  12. Drug abusers or those who have used soft drugs for 3 months before the trial or who took hard drugs one year before the study.
  13. Those who has special requirements for diet and is unable to follow a uniform diet.
  14. Smokers or those who smoked more than 5 cigarettes a day 3 months before the study.
  15. An alcoholic or regular drinker for six months before the study, that is, a person who drinks more than 14 units of alcohol a week.
  16. People who drink excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250 mL) per day or who do not agree to stop drinking tea, coffee and/or caffeinated beverages during the study period.
  17. Those who take drug or food which may affect the drug metabolism(including grapefruit or grapefruit products, dragon fruit, mango, pomelo, orange, yellow purine diet).Or the researchers think that there are other affect drug absorption, distribution, metabolism and excretion of diet.Or refuse to stop eating the diet during the study.
  18. Those with abnormal physical examination, electrocardiogram, laboratory examination, vital signs and test related examination with clinical significance .
  19. Those who has vital signs with clinical significance, positive urine screening test, positive alcohol breath test or positive female urine pregnancy.
  20. Those who has acute illness or concomitant medication occurred before participating in the study.
  21. Other reasons which,in the opinion of the medical investigator,would prevent the subject from participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03771781


Locations
China, Hunan
The Third Hospital of Changsha
Changsha, Hunan, China, 410000
Sponsors and Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ClinicalTrials.gov Identifier: NCT03771781     History of Changes
Other Study ID Numbers: CTTQ-BE-2018-EGLJ
First Posted: December 11, 2018    Key Record Dates
Last Update Posted: December 11, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Empagliflozin
Hypoglycemic Agents
Physiological Effects of Drugs